The Role of MicroRNAs in Lung Cancer Metabolism

Mohamed Iman Hidayat Nor Azizi1, Iekhsan Othman1, Rakesh Naidu1

  • 1Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia.

Cancers
|April 30, 2021
PubMed

Insights

MicroRNAs (miRNAs) play a crucial role in lung cancer by altering cellular metabolism. Understanding miRNA-driven metabolic reprogramming offers new diagnostic and therapeutic strategies for lung cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression involved in various biological processes.
  • Aberrant miRNA expression contributes to tumorigenesis by disrupting normal cellular functions, including metabolism.
  • Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to circumvent normal regulatory mechanisms.

Purpose of the Study:

  • To review the role of microRNAs in the metabolic reprogramming of lung cancer.
  • To elucidate how differential miRNA expression impacts metabolic deregulation in lung cancer.
  • To explore the potential of miRNAs as diagnostic and therapeutic targets in lung cancer management.

Main Methods:

  • Literature review focusing on the relationship between miRNA expression and lung cancer metabolism.
  • Analysis of studies investigating miRNA targeting of key metabolic enzymes, transporters, and signaling pathways.
  • Synthesis of evidence linking miRNA-mediated metabolic changes to lung cancer progression.

Main Results:

  • Differential miRNA expression profiles are associated with varying degrees of metabolic deregulation in localized and advanced lung cancers.
  • miRNAs influence lung cancer progression by targeting critical components of metabolic pathways.
  • Specific miRNAs have been identified as regulators of key enzymes and transporters involved in cancer metabolism.

Conclusions:

  • MicroRNAs are significant drivers of metabolic reprogramming in lung cancer.
  • Targeting miRNA-mediated metabolic alterations presents promising avenues for novel lung cancer diagnostics and therapeutics.
  • A deeper understanding of miRNA functions in tumor metabolism is essential for advancing lung cancer treatment and management.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K